OR WAIT null SECS
Annual Bascom Palmer Eye Institute program will spotlight latest advances in neovascular and exudative ocular disease over 2-day event, February 12-13.
Without skipping a beat amid the pandemic, Bascom Palmer Eye Institute’s 18th annual angiogenesis meeting, “Angiogenesis, Exudation, and Degeneration 2021,” will be held as a virtual event, February 12 and 13.
This year’s program will highlight the latest pharmacotherapies now in the pipeline and those in clinical practice for managing neovascular age-related macular degeneration (AMD), macular edema, diabetic retinopathy, and retinopathy of prematurity with a special focus on the current and future financial impact of these drugs on clinical practices and Medicare.
Retina specialists, general ophthalmologists, and researchers will benefit from the latest information on imaging, translational research, and clinical trials with an emphasis on how these results will impact clinical ophthalmology. The presenters will focus on early-phase clinical trials and recently completed studies on the treatment of a wide range of retinal diseases.
This year’s course co-directors are Philip J. Rosenfeld, MD, PhD, Harry W. Flynn, Jr., MD, and Thomas A. Albini, MD, all from Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami.